Table 1.
Characteristics of studies included in the meta-analysis.
| Study | Country | Study type | Inclusion criteria | Pathological type | N | LVSI+ | LVSI- | Median follow-up | Quality assessment* |
|---|---|---|---|---|---|---|---|---|---|
| Okugawa(2021) | Japan | R | IA | mixed | 297 | 35 | 262 | 60m | 7 |
| Iida(2022) (12) | Japan | R | IA | mixed | 116 | 15 | 101 | 71.9m | 7 |
| Tortorella(2021) (3) | Italia | R | IA G1/G2 | Endometrioid carcinoma | 524 | 57 | 467 | 38m | 7 |
| Reis(2015) (20) | America | R | IA G1/G2 | Endometrioid carcinoma | 200 | 40 | 200 | 46.6m | 8 |
| Nwachukwu(2021) (11) | America | R | IA G1 | Endometrioid carcinoma | 222 | 14 | 204 | 20m | 7 |
| Güngördük(2018) (21) | Turkey | R | IA G1/G2 | Endometrioid carcinoma | 280 | 22 | 258 | 54-69m | 8 |
| Ayhan(2019) (19) | Turkey | R | IA G1/G2 | Endometrioid carcinoma | 912 | 53 | 859 | 42m | 8 |
| Ureyen(2019) | Turkey | R | IA | Endometrioid carcinoma | 720 | 60 | 660 | 48m | 8 |
| Pifer(2022) | Pittsburgh | R | I | Endometrioid carcinoma | 335 | 124 | 211 | 25.8m | 7 |
| Veade(2019) (7) | America | R | I | Endometrioid carcinoma | 275 | 48 | 227 | 54m | 8 |
| Cusano(2018) (9) | Canada | R | I | Endometrioid carcinoma | 400 | 54 | 346 | 66m | 8 |
| Bosse(2015) (22) | Netherlands | R | I | Endometrioid carcinoma | 926 | 70 | 856 | 89-160m | 8 |
| Aristizabal (2014) (23) | France | R | I | mixed | 384 | 112 | 272 | 38.7m | 6 |
| Gemer(2007) (10) | Israel | R | I | mixed | 699 | 40 | 659 | 39m | 6 |
| Yarandi(2023) (6) | Iran | R | I G1/G2 | Endometrioid carcinoma | 415 | 100 | 315 | NM | 6 |
| Total | 6705 | 844 | 5897 |
R, retrospective; G1/G2, grade1/2; NM, not mentioned.
*Quality assessment was measured using the Newcastle-Ottawa Quality Assesment Scale (NOS).